

Pharmacy Hot Tip: Antipsychotics

Your Summit Community Care patients on nonpreferred products may experience a pharmacy claim rejection. To avoid additional steps or delays at the pharmacy, consider prescribing preferred products whenever possible. Prior authorization may apply to select preferred products. Coverage should be verified by reviewing the *Preferred Drug List (PDL)* on the Summit Community Care provider website at https://arkansas.magellanrx.com/provider/docs/rxinfo/PDL.pdf. The *PDL* is subject to change quarterly.

Therapeutic class	Preferred products ¹	Nonpreferred products
Oral antipsychotics	Amitriptyline/Perphenazine tablets	Abilify Mycite tablets
	Aripiprazole (Abilify) tablets	Aripiprazole (Abilify) ODT
	Clozapine (Clozaril) tablets	• Solution
	Fluphenazine tablets	Caplyta (Lumateperone)
	Haloperidol (Haldol) • Lactate Concentrate	Chlorpromazine (Thorazine)
	Solution Tablets	Clozapine (Fazacloz ODT, Versacloz Suspension)
	Loxapine capsules	Fanapt tablets
	Olanzapine (Zyprexa) • Tablets • ODT	Fluoxetine/Olanzapine (Symbyax) capsules
		Fluphenazine Oral Concentrate
	Paliperidone (Invega) tablets	Latuda tablets
	Perphenazine (Trilafon) tablets	Molindone (Moban) tablets
	Pimozide (Orap) tablets	Quetiapine ER (Seroquel XR)
	Quetiapine (Seroquel) tablets	Rexulti tablets
	Risperidone (Risperdal) • Tablets	Saphris SL tablets
	ODTSolution	Vraylar capsules
	Thioridazine tablets	
	Thiothixene capsules	
	Trifluoperazine tablets	

ARPEC-0970-21 03/04/2021

	Ziprasidone (Geodon) capsules	
Long Acting Injectable	Abilify Maintena	Perseris
Antipsychotics	Aristada	Zyprexa Relprevv³
	Fluphenazine Decanoate	
	Haloperidol Decanoate (Haldol)	
	Invega Sustenna ²	
	Invega Trinza ²	
	Risperdal Consta	

¹ Preferred products may require additional review for age < 18. For age < 18, criteria requirements include copy of baseline metabolic lab test data (glucose and lipid screening) and signed informed consent. ODT and solutions are preferred only for ages < 7 or patients with a diagnosis of NPO in history. Please refer to the criteria document found on our website for more information.

- 2 Invega Sustenna and Invega Trinza are now preferred effective October 1, 2020.
- 3 Zyprexa Relprevv is now nonpreferred effective October 1, 2020.

Brand names are listed in parentheses for reference only. If generics are available, brand products are nonpreferred.

If you have questions regarding this *Hot Tip*, call Provider Services at **1-844-462-0022**.